Glenmark Pharmaceuticals has received final approval for generic version of Temovate Topical Solution, from the US health regulator. It is used to treat certain scalp and skin conditions.

In a BSE filing the company stated, “Glenmark Pharmaceuticals USA has been granted final approval by the US Food and Drug Administration (USFDA) for Clobetasol Propionate Topical Solution USP, 0.05%.”

The approved product will be manufactured at its Baddi plant. Moreover, the company has 133 products authorized for distribution at the US marketplace and 60 abbreviated new drug applications (ANDA) pending approval with the USFDA.

Read EquityPandit’s Technical Analysis of Nifty Pharma